GAMMAGARD LIQUID SC
Subcutaneous (SC) administration may be the right choice for your patients.
Protect life's moments with:
- Demonstrated tolerability1,a
- An established safety profile1
- A manageable infusion time
- Sustained protection against infection1
- Maintenance of consistent IgG serum trough levels during the 12 months of treatment1,2
aThe safety of GAMMAGARD LIQUID in SC infusions was evaluated in 47 subjects.
Selected Important Risk Information
- The most common adverse reactions observed in ≥ 5% of patients in the clinical trials for PI (SC administration) were: Infusion site (local) event, headache, fatigue, heart rate increased, pyrexia, abdominal pain upper, nausea, vomiting, asthma, blood pressure systolic increased, diarrhea, ear pain, aphthous stomatitis, migraine, oropharyngeal pain, and pain in extremity.
References: 1. GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% [Prescribing Information]. Westlake Village, CA: Baxalta US Inc. 2. Wasserman RL, Melamed I, Kobrynski L, et al. Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. J Clin Immunol. 2011;31(3):323-331.